Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1316-1323

  Vose, Julie M ^a   Wahl, Richard L ^a   Saleh, Mansoor ^a   Rohatiner, Ama Z ^a   Knox, Susan J ^a   Radford, John A ^a   Zelenetz, Andrew D ^a   Tidmarsh, George F ^a   Stagg, Robert J ^a   Kaminski, Mark S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY; TOSITUMOMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER RECURRENCE; CLINICAL TRIAL; DOSIMETRY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034017954     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1316     Document Type: Article

References (34)

1. Longo DL, DeVita VT, Jaffe E, et al: Lymphocytic lymphomas, in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, JB Lippincott, 1993, pp 1859-1927
2. Reddy S, Saxena VS, Pellettiere EV, et al: Stage I and II non-Hodgkin's lymphomas: Long-term results of radiation therapy. Int J Radiat Oncol Biol Phys 6:687-692, 1989
3. Johnson PM, Rohatiner AS, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
4. Portlock CS, Rosenberg SA: No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 90:10-13, 1979
5. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 311: 1471-1475, 1984
6. Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 13:2656-2675, 1995
7. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-451, 1997
8. Horning SJ: Treatment approaches to the low-grade lymphomas. Blood 83:881-897, 1994
9. Brown SL, Miller RA, Horning SJ, et al: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha-interferon. Blood 73:651-661, 1989
10. Meeker TC, Lowder J, Maloney DG, et al: A clinical trial of anti-idiotype therapy for B-cell malignancy. Blood 65a:1349-1363, 1985
11. Liu SY, Press OW: The potential for immunoconjugates in lymphoma therapy. Hematol Oncol Clin North Am 11:987-1006, 1997
12. Renner C, Trumper L, Pfreundschuh M: Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma: Recent results and future prospects. Leukemia 11:S55-S59, 1997 (suppl 2)
13. Hale G, Dyer MJS, Clark MR, et al: Remission induction in non-Hodgkin's lymphoma with the reshaped human monoclonal antibody CAMPATH-1H. Lancet 2:1394-1399, 1988
14. Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591, 1987
15. McLaughlin P, Grillo-Lopez A, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
16. Buchsbaum DJ, Wahl RL, Normolle DP, et al: Therapy with unlabeled and 131-I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 52: 6476-6481, 1992
17. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497-1515, 1994
18. Colcher D: Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med 39:11S-13S, 1998 (suppl)
19. Stagg R, Wahl RL, Estes J, et al: Phase I/II study of iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma (NHL): Final results. Proc Am Soc Clin Oncol 17:39a, 1998 (abstr 150)
20. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219-1224, 1993
21. Press OW, Eary JF, Appelbaum FR, et al: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet 346:336-340, 1995
22. Salacinski RP, McLean C, Sykes JEF, et al: Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent 1,3,4,6-tetrachloro-3a-6a-diphenylglycouril (Iodogen). Anal Biochem 117:136-146, 1981
23. Loevinger R, Budinger TF, Watson EE: MIRD Primer for Absorbed Dose Calculations. Reston, VA, The Society of Nuclear Medicine Inc, 1988
24. Wahl RL, Kroll S, Zasadny DR: Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med 39:14S-20S, 1998 (suppl)
25. Sgouros G: Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34:689-694, 1993
26. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
27. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
28. Emami B, Lyman J, Brown A, et al: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109-122, 1991
29. Solal-Celigny P, Lepage E, Brousse N, et al: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol 16:2332-2338, 1998
30. Bastion Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 15:1587-1594, 1997
31. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131 anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-1981, 1996
32. Siegel JA: Revised nuclear regulatory commission regulations for release of patients administered radioactive materials: Outpatient Iodine-131 anti-B1 therapy. J Nucl Med 39:28S-33S, 1998 (suppl)
33. Kaminski MS, Estes J, Regan D, et al: Front-line treatment of advanced B-cell low-grade lymphoma (LGL) with radiolabeled iodine I 131 tositumomab: Initial experience. Proc Am Soc Clin Oncol 16:15a, 1997 (abstr 51)
34. Knox SJ, Goris ML, Davis TA, et al: Randomized controlled study of iodine I 131 tositumomab vs. unlabeled anti-B1 antibody in patients with chemotherapy refractory low-grade non-Hodgkin's lymphoma (abstract). Presented at the poster session of the Am Soc Ther Radiol Oncol (ASTRO) 39th Annual Meeting, Orlando, FL, October 19-23, 1997